A Phase 2 interventional study of ENN0403, low dose and ENN0403, high dose in Diabetic Macular Edema (DME), sponsored by EnnovaBio. Completed at 9 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by EnnovaBio · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Macular Edema with a site in China — 18 open to participants now, 22 under way, 4 of them phase 3. Macular Edema · China.
Among the 72 studies in Macular Edema with a site in China, this one is the 47th largest by enrollment of the 65 interventional ones that give a count, is one of 10 that started in 2024, is one of 4 in phase 2, and was the 61st registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →18 of the 72 studies in Macular Edema with a site in China are open now. Recruiting first, the newest first:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18–80
Boehringer Ingelheim · Sites in China, United States, Czechia and 6 more countries
Ages 18+
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in China, United States, Australia
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 12 · Phase 3 26 · Phase 4 9
First in 2003; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is close to the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 140 across the 65 interventional studies, 110 across the 7 observational. Of the 38 that completed or were terminated, 13 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 72 have an industry lead sponsor. The 10 most frequent:
EnnovaBio is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
EnnovaBio has 1 study filed under Macular Edema — fewer than ten, so there is no comparison to draw.
5 of the studies in Macular Edema with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07515079Phase 3Bio-Thera SolutionsEfficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema | 2027-04-30 |
| NCT07019896Peking Union Medical College HospitalMinimal Vitrectomy Surgery for Epiretinal Membrane | 2026-11-30 |
| NCT06548568AbbVieA Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China | 2027-04 |
| NCT07133438First Affiliated Hospital of Chongqing Medical UniversityMecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment | 2027-05-31 |
| NCT07362927Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineSafety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 72 studies in Macular Edema with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, parallel study to evaluate the efficacy and safety of two doses of ENN0403 in subjects with diabetic macular edema (DME). Approximately 60 subjects will be randomized to receive ENN0403 capsule orally once a day at the low dose or high dose with a 1:1 ratio. The study period consisted of up to 2 weeks of screening, 12 weeks of treatment and 2 weeks of follow-up, and the entire trial period was up to 16 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ENN0403, low dose
Drug: ENN0403, high dose
ENN0403 capsules will be orally administered once a day for 12 weeks.
ENN0403 capsules will be orally administered once a day for 12 weeks.
Change from baseline in Central Retinal Thickness (CRT) at week 12
Time frame: week 12
Change from baseline in Best Corrected Visual Acuity (BCVA) at week 4, 8, and 12
Time frame: week 4, 8, 12
Change from baseline in CRT at week 4 and 8
Time frame: week 4, 8
Incidence of ocular and non-ocular TEAE and SAE
Time frame: 12 weeks
Ran from Dec 2024 to primary completion in Aug 2026, 20 months.
Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 20 months is above that.
Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Dec 2025 → Aug 2026 and completion Feb 2026 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ENN0403
EnnovaBio